ELAN, ALZA DELIVER STRONG GAINS IN FIRST QUARTER AS FIRMS ENHANCE DRUG DEVELOPMENT EFFORTS; NOVARTIS MERGER SPAWNS RUMORS OF STILL MORE Rx DEALS
Executive Summary
Elan's diversification from drug delivery into drug discovery has won the company an enthusiastic following on Wall Street. The stock posted a 32% gain for the first quarter, closing at 64-1/4.